Bedford, MA (October 2015) — First Light Biosciences, a developer of breakthrough automated diagnostic products for rapid, sensitive and cost-effective detection of Healthcare Associated Infections (HAI) announced today a contract with the Biomedical Advanced Research and Development Authority to develop rapid, sensitive, and easy-to-use anthrax tests. The contract supports the project with $5.5 million over 16 months and up to a total of $42.9 million over 6 years if all options are exercised.
According to the BARDA announcement, “The new test is part of BARDA’s comprehensive integrated portfolio approach to the advanced research and development, innovation, acquisition, and manufacturing of vaccines, drugs, therapeutics, diagnostic tools, and non-pharmaceutical products for public health emergency threats. These threats include chemical, biological, radiological, and nuclear (CBRN) agents, pandemic influenza, and emerging infectious diseases.”
About First Light Biosciences
Based in Bedford, Massachusetts, First Light Biosciences is developing breakthrough automated medical diagnostic products for rapid, sensitive, and cost-effective detection of Healthcare Associated Infections (HAI). The products address the need for cost-effective and accurate diagnostics to meet the explosive growth in testing. New testing is being driven by clinical studies showing that testing for the infectious agents can help to dramatically lower the rate of hospital infections. Based on its proprietary MultiPath™ detection technology, First Light’s products combine the performance of the most advanced commercial laboratory tests with affordability and ease-of-use. To learn more, visit www.firstlightibio.com